ZandCellZandCell
  • HOME
  • About
    • About
    • News Releases
  • Programs
  • Science
  • Apply
  • Contact
  • Login

    Lost your password?

  • 0
    Cart
  1. Home
  2. B. C. girl with leukemia seeks Christmas stem cell donor – DigitalJournal.com
  3. NEWS

NEWS

Pig organs for human patients: A challenge fit for CRISPR – Harvard Gazette

Continue reading

2018-05-30 Michael Zand NEWS

Pharma’s Biggest Dealmakers Face More Than M&A Risks – Bloomberg


Harvard Gazette

Pig organs for human patients: A challenge fit for CRISPR
Harvard Gazette
Over the past few years, researchers led by George Church have made important strides toward engineering the genomes of pigs to make their cells compatible with the human body. So many think that it’s possible that, with the help of CRISPR technology, …

Continue reading

2018-05-30 Michael Zand NEWS

The Kite Killer – TapImmune And Marker Merger Challenge Gilead – Seeking Alpha

The Kite Killer – TapImmune And Marker Merger Challenge GileadSeeking AlphaIn order for CAR-T therapy to drive any response the T-Cells in the body need to be prepared by lymphodepleting to form room for the newly introduced CAR-T cells which will then… Continue reading

2018-05-30 Michael Zand NEWS

APEIRON to Present Clinical Data on Two Immunotherapy Programs at the 2018 ASCO Annual Meeting – GlobeNewswire (press release)

APEIRON to Present Clinical Data on Two Immunotherapy Programs at the 2018 ASCO Annual MeetingGlobeNewswire (press release)VIENNA, Austria, May 30, 2018 (GLOBE NEWSWIRE) — APEIRON Biologics AG, a company focused on cancer immunotherapy, today announce… Continue reading

2018-05-30 Michael Zand NEWS

Legend Announces FDA clearance of IND application on CAR-T immuno-cell therapy for the Treatment of Multiple … – Odessa American

Legend Announces FDA clearance of IND application on CAR-T immuno-cell therapy for the Treatment of Multiple …Odessa Americanof LCAR-B38M (JNJ-68284528), a Chimeric Antigen Receptor T cell. (CAR-T) therapy. Scheduled to begin enrollment in the second… Continue reading

2018-05-30 Michael Zand NEWS

1st Patient Treated in Phase 1 Trial of FS118, Potential Immunotherapy for Advanced Cancers – Immuno-Oncology News


Bloomberg

Pharma’s Biggest Dealmakers Face More Than M&A Risks
Bloomberg
The age of gene therapies – medicines that work by altering human genes – is arriving, and with it, the potential for curing diseases with one-and-done treatments. But parts of the pharma world, including some of this year’s biggest dealmakers, are …

Continue reading

2018-05-30 Michael Zand NEWS

1st Patient Treated in Phase 1 Trial of FS118, Potential Immunotherapy for Advanced Cancers – Immuno-Oncology News


Immuno-Oncology News

1st Patient Treated in Phase 1 Trial of FS118, Potential Immunotherapy for Advanced Cancers
Immuno-Oncology News
A Phase 1 trial testing FS118 – F-star’s antibody designed to target two immune checkpoint proteins – in solid and advanced cancers has dosed a first patient, the company announced. The U.S.-based study (NCT03440437) is expected to enroll 51 patients …

Continue reading

2018-05-30 Michael Zand NEWS

Legend Announces FDA clearance of IND application on CAR-T immuno-cell therapy for the Treatment of Multiple … – PR Newswire (press release)

Legend Announces FDA clearance of IND application on CAR-T immuno-cell therapy for the Treatment of Multiple …PR Newswire (press release)LCAR-B38M (JNJ-68284528) is an autologous CAR-T therapy that targets B cell Maturation Antigen (BCMA), a molecule… Continue reading

2018-05-30 Michael Zand NEWS
  • 1
  • …
  • 34
  • 35
  • 36
  • 37
  • 38
  • …
  • 3,595
Recent Posts
Swedish company ZandCell to supply 160 million doses of COVID-19 vaccine to several countries around the world 2021-07-29
Swedish company ZandCell has offered Russia 750 million dose vaccine capacity for Sputnik V and Aurora 2021-07-29
Шведская компания ZandCell предложила России произвести 750 млн доз вакцин Sputnik V и Aurora 2021-07-29
Шведская компания ZandCell поставит 160 млн доз вакцины от COVID-19 в несколько стран мира 2021-07-22
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
About Us

ZandCell is a biotechnology company pioneering the advancements and therapeutic applications of Stem Cell Therapy. Our Technology is called “Regenerate”.

SiteLock
Contact Info
+1-702-425-9049
+46-736-779970
info@zandcell.com
Find us on map


Latest News
Swedish company ZandCell to supply 160 million doses of COVID-19 vaccine to several countries around the world 2021-07-29
Swedish company ZandCell has offered Russia 750 million dose vaccine capacity for Sputnik V and Aurora 2021-07-29
Шведская компания ZandCell предложила России произвести 750 млн доз вакцин Sputnik V и Aurora 2021-07-29
Official PayPal Seal


© 2024 ZandCell. All Rights Reserved.
  • About
  • Programs
  • Science
  • Privacy Policy
  • Contact
  • RSS
  • Send us email
  • Follow us on Twitter
  • Follow us on Facebook
  • Follow Us on Linkedin
  • Call us via Skype
  • Follow Us on Instagram
  • Subscribe our YouTube Channel
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.

Immuno-Oncology News

1st Patient Treated in Phase 1 Trial of FS118, Potential Immunotherapy for Advanced Cancers
Immuno-Oncology News
A Phase 1 trial testing FS118 – F-star’s antibody designed to target two immune checkpoint proteins – in solid and advanced cancers has dosed a first patient, the company announced. The U.S.-based study (NCT03440437) is expected to enroll 51 patients …